{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:04:57Z","timestamp":1785387897993,"version":"3.55.0"},"reference-count":53,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,12,29]],"date-time":"2011-12-29T00:00:00Z","timestamp":1325116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Statins reduce atherosclerosis and cardiovascular morbidity in the general population, but their efficacy and safety in children and adolescents with systemic lupus erythematosus (SLE) are unknown. This study was undertaken to determine the 3\u2010year efficacy and safety of atorvastatin in preventing subclinical atherosclerosis progression in pediatric\u2010onset SLE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 221 participants with pediatric SLE (ages 10\u201321 years) from 21 North American sites were enrolled in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus study, a randomized double\u2010blind, placebo\u2010controlled clinical trial, between August 2003 and November 2006 with 36\u2010month followup. Participants were randomized to receive atorvastatin (n = 113) or placebo (n = 108) at 10 or 20 mg\/day depending on weight, in addition to usual care. The primary end point was progression of mean\u2010mean common carotid intima\u2010media thickening (CIMT) measured by ultrasound. Secondary end points included other segment\/wall\u2010specific CIMT measures, lipid profile, high\u2010sensitivity C\u2010reactive protein (hsCRP) level, and SLE disease activity and damage outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Progression of mean\u2010mean common CIMT did not differ significantly between treatment groups (0.0010 mm\/year for atorvastatin versus 0.0024 mm\/year for placebo; <jats:italic>P<\/jats:italic> = 0.24). The atorvastatin group achieved lower hsCRP (<jats:italic>P<\/jats:italic> = 0.04), total cholesterol (<jats:italic>P<\/jats:italic> &lt; 0.001), and low\u2010density lipoprotein (<jats:italic>P<\/jats:italic> &lt; 0.001) levels compared with placebo. In the placebo group, CIMT progressed significantly across all CIMT outcomes (0.0023\u20130.0144 mm\/year; <jats:italic>P<\/jats:italic> &lt; 0.05). Serious adverse events and critical safety measures did not differ between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results indicate that routine statin use over 3 years has no significant effect on subclinical atherosclerosis progression in young SLE patients; however, further analyses may suggest subgroups that would benefit from targeted statin therapy. Atorvastatin was well tolerated without safety concerns.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.30645","type":"journal-article","created":{"date-parts":[[2011,10,26]],"date-time":"2011-10-26T20:16:41Z","timestamp":1319660201000},"page":"285-296","source":"Crossref","is-referenced-by-count":153,"title":["Use of atorvastatin in systemic lupus erythematosus in children and adolescents"],"prefix":"10.1002","volume":"64","author":[{"given":"L. E.","family":"Schanberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sandborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. X.","family":"Barnhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Ardoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Yow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. W.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. L.","family":"Mieszkalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. T.","family":"Ilowite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Eberhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. F.","family":"Imundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"von Scheven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L.","family":"Bowyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Punaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. G.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. D.","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Klein\u2010Gitelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wagner\u2010Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. C.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. I.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"Soep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Provenzale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,29]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"223","article-title":"Morbidity in systemic lupus erythematosus","volume":"14","author":"Gladman DD","year":"1987","journal-title":"J Rheumatol"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009122"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035471"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24537"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20122"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23204"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307087875"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1515\/IJAMH.2007.19.4.497"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200006)43:6<1405::AID-ANR26>3.0.CO;2-V"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24469"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20392"},{"key":"e_1_2_8_13_2","first-page":"1345","article-title":"Relation of arterial stiffness to left ventricular structure and function in adolescents and young adults with pediatric\u2010onset systemic lupus erythematosus","volume":"34","author":"Chow PC","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70494-9"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2376"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2008.08.022"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.3.331"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi695"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:CARD.0000033645.55138.3d"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X182121"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0892-0362(95)91641-W"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199902000-00003"},{"key":"e_1_2_8_27_2","unstructured":"National Cancer Institute. Common toxicity criteria version 2.0. URL:http:\/\/ctep.cancer.gov\/forms."},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21441"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000102044.27905.B5"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009302"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1432"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901073400103"},{"key":"e_1_2_8_33_2","first-page":"S520","article-title":"Lupus Atherosclerosis Prevention Study (LAPS): randomized double blind placebo controlled trial of atorvastatin versus placebo","volume":"54","author":"Petri M","year":"2006","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24379"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.109405"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem381"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0341-6"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/1468-6708-6-3"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.628875"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2010.499132"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23196"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199816110-00005"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000178834.26353.d5"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(02)00330-1"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.12.1344"},{"key":"e_1_2_8_47_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/089686080602600503","article-title":"Statins for treatment of dyslipidemia in chronic kidney disease","volume":"26","author":"Shurraw S","year":"2006","journal-title":"Perit Dial Int"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D"},{"key":"e_1_2_8_49_2","first-page":"2458","article-title":"Predictors of carotid atherosclerosis in systemic lupus erythematosus","volume":"33","author":"Maksimowicz\u2010McKinnon K","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22924"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.03.016"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0046"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0789"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000061521.15730.6E"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.30645","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.30645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T18:56:20Z","timestamp":1696964180000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.30645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,29]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/art.30645"],"URL":"https:\/\/doi.org\/10.1002\/art.30645","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,29]]}}}